Cargando…
Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
OBJECTIVES: Imiquimod is an immune response modifier that has demonstrated a good efficacy and relatively low recurrence rates in comparison to other genital wart treatment modalities. The primary objective of this open-label study was to evaluate the effect on sustained clearance of treated lesions...
Autores principales: | Hoyme, U B, Hagedorn, M, Schindler, A E, Schneede, P, Hopfenmüller, W, Schorn, K, Eul, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784609/ https://www.ncbi.nlm.nih.gov/pubmed/12530484 |
Ejemplares similares
-
Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies
por: Baker, David A., et al.
Publicado: (2011) -
Early Treatment with Imiquimod 5% Cream of Periungual Warts in Vietnam: The Poorer, the Better
por: Minh, Phuong Pham Thi, et al.
Publicado: (2019) -
Anogenital warts in pediatric population
por: Costa-Silva, Miguel, et al.
Publicado: (2017) -
Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts
por: Braun, Stephan A., et al.
Publicado: (2022) -
Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)
por: Murray, Macey L., et al.
Publicado: (2018)